T cells and innate lymphoid cells (ILCs) in cutaneous graft-versus-host disease

Withdrawn

• Conditions: Graft-versus-host disease; Graft-versus-host reaction; 10018849; 10027665; 10040790

• Registration Number: NL-OMON46564
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Patients with Graft-versus-host disease
- Male and female
- * 18 years of age
- Patient is willing and able to give written informed consent

Exclusion Criteria

- Patients taking anticoagulant medication

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Hypothesis: Pathogenic alloreactive clones in GvHD expand in skin during<br /><br>rejection and may be present in blood at low levels, capable of being detected<br /><br>by the newly developed High-throughput TCR deep sequencing. Moreover these<br /><br>pathogenic clones may differ in their function during times of rejection versus<br /><br>tolerance.<br /><br><br /><br>To evaluate this hypothesis, we will carry out experimentswith the following<br /><br>specific aims:<br /><br><br /><br>Aim 1: to identify pathogenic T cell and ILC clones expanded in GvHD skin<br /><br>lesions.<br /><br>Aim 2: to study the function and possible pathogenicity of T cell and ILC<br /><br>clones identified in Aim 1.<br /><br>Aim 3: to track the pathogenic T cell and ILC clones identified in Aim 1 in the<br /><br>blood of the same GvHD patients in times of tolerance versus GvHD, and study<br /><br>their function and phenotypic plasticity.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>